300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Retail
Social Impact
SaaS
Cryptocurrency
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Hospitality
Sports
Legal
eSports
Biotechnology
Construction
Consumer
Renewable Energy
Software
Crowdfunding
Venture Capital
Theatre
Medical
Fashion
Recruiting
Social
Web3
Cannabis
Beauty
LGBT
Celebrity
Climate
Infrastructure
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Manufacturing
Digital Media
FinTech
Finance
Art
Financial Services
Social Media
Franchise
Mobile Advertising
Real Estate
Non Profit
Internet
Android
Sporting Goods
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Gibraltar
Singapore
Brazil
Kyrgyzstan
LATAM
Liberia
Africa
Taiwan
Oceania
Mexico
Tunisia
Nigeria
Russian Federation
Togo
Guinea
Nepal
Sweden
Iran
Isle of Man
Madagascar
Pakistan
Zimbabwe
Zambia
Romania
Norway
Tajikistan
Poland
Oman
Puerto Rico
Andorra
Cameroon
Guernsey
Sudan
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Turkey
Myanmar
Uganda
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Canada
Georgia
Denmark
Ghana
United Kingdom
Iraq
Mali
Latvia
Malaysia
Portugal
Sierra Leone
Philippines
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Angola
Europe
Cyprus
Qatar
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Belize
Faroe Islands
Finland
Estonia
Italy
Belarus
Hungary
Jersey
Bahrain
Grenada
Israel
Iceland
Liechtenstein
Lebanon
Cambodia
Honduras
Lithuania
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Mark Krul, Partner at Aglaia BioMedical Ventures

Mark Krul

Partner @ Aglaia BioMedical Ventures

Utrecht, The Netherlands

Mark Krul is a seed investor at Aglaia BioMedical Ventures in Utrecht focused on Biotechnology and Pharmaceutical. Mark Krul

Total investments:
1
Last investment:
Lead investor:
0%

Last updated:

Industries Mark Krul invests in

BiotechnologyPharmaceutical

Stages Mark Krul invests in

Seed

Countries Mark Krul invests in

Switzerland

Investment Focus

Industry

  • Biotechnology 1 (100%)
  • Pharmaceutical 1 (100%)

Investments

CompanyDescriptionRoundLinks
Inthera Bioscience Inthera Bioscience
Inthera Bioscience is a Switzerland-based private biopharmaceutical company developing targeted small molecule therapies for solid tumors. It is focused on developing inhibitors of intracellular protein-protein interactions employing a proprietary technology platform. The company is headquartered in Zürich, Switzerland. $3.7M / Seed / Dec 14, 2015

Co-Investors

Microsoft Accelerator Microsoft Accelerator 1 deal together
Novo Holdings Novo Holdings 1 deal together
Aglaia BioMedical Ventures

About Aglaia BioMedical Ventures

VC Fund · Bilthoven, The Netherlands

Aglaia is founded on the principle that the willingness to take risks on the very early stage ventures of today results in opportunities that may grow into the winning companies of tomorrow. As such, we are typically the first provider of capital for startup and early stage companies and a driving force behind product development. Since thenumber of technological discoveries in the biomedical field is growing fast, specialized knowledge regarding the translation of these discoveries into novel products is a prerequisite for success. Aglaia's focus on oncology is considered to be a differentiating asset. We invest in novel tools and technologies as well as components of contemporary drug development.Opportunities may be derived from research centers as well as from corporate spinouts. We select, develop and commercialize promising technologies up to a level where the technology becomes attractive to larger investors or pharmaceutical and biotech companies.

Aglaia BioMedical Ventures Contacts

NameEmailPhoneSocials
Mark Krul
Mark Krul Partner

Sign up to unlock verified contacts

Unlock Contacts

4 more contacts available

Open Aglaia BioMedical Ventures full profile

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
Oil and Gas
InsurTech
Retail
Social Impact
SaaS
Cryptocurrency
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
Social Network
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Hospitality
Sports
Legal
eSports
Biotechnology
Construction
Consumer
Renewable Energy
Software
Crowdfunding
Venture Capital
Theatre
Medical
Fashion
Recruiting
Social
Web3
Cannabis
Beauty
LGBT
Celebrity
Climate
Infrastructure
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Manufacturing
Digital Media
FinTech
Finance
Art
Financial Services
Social Media
Franchise
Mobile Advertising
Real Estate
Non Profit
Internet
Android
Sporting Goods
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Gibraltar
Singapore
Brazil
Kyrgyzstan
LATAM
Liberia
Africa
Taiwan
Oceania
Mexico
Tunisia
Nigeria
Russian Federation
Togo
Guinea
Nepal
Sweden
Iran
Isle of Man
Madagascar
Pakistan
Zimbabwe
Zambia
Romania
Norway
Tajikistan
Poland
Oman
Puerto Rico
Andorra
Cameroon
Guernsey
Sudan
Colombia
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Turkey
Myanmar
Uganda
Uruguay
Botswana
Moldova
Seychelles
Paraguay
Ireland
Japan
South Africa
France
Canada
Georgia
Denmark
Ghana
United Kingdom
Iraq
Mali
Latvia
Malaysia
Portugal
Sierra Leone
Philippines
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Middle East
Indonesia
Dominican Republic
Bermuda
Asia
Albania
Spain
Argentina
Angola
Europe
Cyprus
Qatar
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Bahamas
Ecuador
Bolivia
Algeria
Belize
Faroe Islands
Finland
Estonia
Italy
Belarus
Hungary
Jersey
Bahrain
Grenada
Israel
Iceland
Liechtenstein
Lebanon
Cambodia
Honduras
Lithuania
Mongolia
Slovenia
Peru
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Mark Krul invest in?

Mark Krul invests primarily in Biotechnology and Pharmaceutical startups, most often at Seed stage. Most of the 1 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Mark Krul last invest?

The most recent investment recorded for Mark Krul closed in Dec 2015. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Mark Krul Mark Krul Find email